Junli He Net Worth

The estimated Net Worth of Junli He is at least $948 mil dollars as of 12 December 2022. Junli He owns over 135 units of Biostage stock worth over $947,050 and over the last 3 years Junli sold BSTG stock worth over $922.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Junli He BSTG stock SEC Form 4 insiders trading

Junli has made over 1 trades of the Biostage stock since 2022, according to the Form 4 filled with the SEC. Most recently Junli sold 135 units of BSTG stock worth $922 on 12 December 2022.

The largest trade Junli's ever made was selling 135 units of Biostage stock on 12 December 2022 worth over $922. On average, Junli trades about 27 units every 0 days since 2021. As of 12 December 2022 Junli still owns at least 235,000 units of Biostage stock.

You can see the complete history of Junli He stock trades at the bottom of the page.

What's Junli He's mailing address?

Junli's mailing address filed with the SEC is 84 OCTOBER HILL RD, SUITE 11, HOLLISTON, MA, 01746.

Insiders trading at Biostage

Over the last 8 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst, eRonald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.

What does Biostage do?

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Complete history of Junli He stock trades at Biostage

Biostage executives and stock owners

Biostage executives and other stock owners filed with the SEC include:

• David Green,
  Director
• Dr. William L. Fodor Ph.D.,
  Chief Scientific Officer
• Yu Hong,
  Pres
• Thomas Robinson,
  Independent Director
• James Shmerling,
  Director
• Ting Li,
  Director
• Harout DerSimonian,
  Chief Scientific Officer
• James Mastridge,
  Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
• Hong Yu,
  President
• Jason Jing Chen,
  Chairman of the Board
• Dr. Shunfu Hu Ph.D.,
  VP of Bus. Devel. & Operations
• Peter A. Pellegrino Jr.,
  Interim VP of Fin.
• David Green,
  CEO & Chairman
• Blaine H. Mc Kee,
  Director
• Saverio La Francesca,
  See Remarks
• John J Canepa,
  Director
• Thomas Mc Naughton,
  Chief Financial Officer
• John F Kennedy,
  Director
• James Joseph Mc Gorry,
  Chief Executive Officer
• William Fodor,
  Chief Scientific Officer
• Herman Sanchez,
  Director
• Xiaoyu Du,
  10% owner
• Matthew D Dallas,
  Director
• Wei Zhang,
  Director
• Jeffrey E Young,
  Director
• Peter M Chakoutis,
  Vice President of Finance
• Ronald J Packard,
  Director
• Capital Llc Dst,
  10% owner
• Jing Chen,
  
• Junli He,
  CEO
• Joseph Luis Jr Damasio,
  Chief Financial Officer